Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TScan Therapeutics Inc TCRX

Healthcare Biotechnology
TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of T cell receptor-engineered T cell (TCR-T), therapies for the treatment of patients with cancer. The Company’s lead TCR-T therapy candidates, TSC-100 and TSC-101, are in clinical development for the treatment of patients with hematologic malignancies to eliminate residual... see more

Recent & Breaking News (NDAQ:TCRX)

TScan Therapeutics Appoints Seasoned Hematology and Oncology Expert Chrystal U. Louis, M.D., M.P.H., as Chief Medical Officer

GlobeNewswire April 8, 2024

TScan Therapeutics Announces Upcoming Presentation at the 23rd Annual Needham Virtual Healthcare Conference

GlobeNewswire April 2, 2024

TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire March 6, 2024

TScan Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference

GlobeNewswire February 28, 2024

TScan Therapeutics Presents Promising Updated Phase 1 Clinical Results on TSC-100 and TSC-101 at the 2024 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire February 26, 2024

TScan Therapeutics to Host Virtual KOL Event to Discuss Updated Results from Phase 1 Heme Malignancies Study Presented at the 2024 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire February 14, 2024

TScan Therapeutics Expands Clinical Team with the Appointment of Dawn Pinchasik, M.D., M.S., as Vice President, Clinical Development

GlobeNewswire February 6, 2024

TScan Therapeutics Appoints Seasoned Industry Executive Jason A. Amello as Chief Financial Officer

GlobeNewswire January 29, 2024

TScan Therapeutics Announces Best Abstracts Award and Upcoming Oral Presentation at the 2024 Tandem Meetings of ASTCT and CIBMTR

GlobeNewswire January 18, 2024

TScan Therapeutics Announces 2024 Clinical Plans and Highlights Recent Progress

GlobeNewswire January 4, 2024

TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire December 9, 2023

TScan Therapeutics Appoints R. Keith Woods to its Board of Directors, Bringing Expertise in Commercialization and Global Operations

GlobeNewswire December 7, 2023

TScan Therapeutics to Host Virtual KOL Event to Discuss Results from Ongoing Phase 1 Trial of TSC-100 and TSC-101 Presented at the 65th ASH Annual Meeting and Exposition

GlobeNewswire December 4, 2023

TScan Therapeutics Expands Manufacturing Leadership with the Appointment of Justin McCue, Ph.D., as Chief Technology Officer

GlobeNewswire December 4, 2023

TScan Therapeutics Named Top Place to Work by The Boston Globe for Two Consecutive Years

GlobeNewswire November 30, 2023

TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2023

TScan Therapeutics Presents Phase 1 Trial Design for Solid Tumor Program at the Society for Immunotherapy of Cancer 38th Annual Meeting

GlobeNewswire November 6, 2023

TScan Therapeutics Announces Upcoming Presentation at the 65th American Society of Hematology Annual Meeting and Exposition

GlobeNewswire November 2, 2023

TScan Therapeutics Announces Upcoming Presentations at the 38th Society for Immunotherapy of Cancer Annual Meeting

GlobeNewswire September 27, 2023

TScan Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire September 5, 2023